AORN San Giuseppe Moscati Avellino

The site’s Onco-Ematologia department is strongly focused on neoplasms and hemic and lymphatic diseases, with a large share of studies exploring better ways to treat lung cancer, colorectal cancer, breast cancer, and ovarian cancer. Many trials are designed to test new treatment strategies and improve outcomes for patients with advanced or recurrent disease.

• Studies in non-small cell lung cancer are evaluating new immunotherapy and targeted therapy combinations to improve survival and disease control.
• Research in colorectal cancer is examining personalized treatment approaches for mutation-defined and metastatic disease.
• Several trials in breast cancer and ovarian cancer are focused on adjuvant and maintenance therapies to reduce recurrence.

This research activity reflects a broad effort to refine cancer care, from first-line treatment choices to approaches that may help prevent relapse and extend long-term benefit.

A major part of the clinical research at this hospital centers on hematologic malignancies and related blood disorders, especially acute leukemia, lymphoma, and myelodysplastic and marrow-related conditions. These studies aim to improve remission rates, deepen molecular responses, and support more effective care for patients with difficult-to-treat disease.

• Trials in acute myeloid leukemia and acute lymphoblastic leukemia are investigating new ways to achieve stronger and more durable remission.
• Research in diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin’s lymphoma is testing treatment strategies that may improve disease control and reduce treatment burden.
• Studies in paroxysmal nocturnal hemoglobinuria, warm autoimmune hemolytic anemia, and thrombotic microangiopathy are assessing therapies aimed at better managing complex blood-related conditions.

The overall focus is on advancing both standard and innovative options for patients with aggressive or relapsed blood cancers and immune-mediated hematologic diseases.

The trial portfolio at AORN San Giuseppe Moscati Avellino shows extensive work in targeted therapy and immunotherapy for advanced solid tumors. Research is especially active in non-small cell lung cancer and metastatic colorectal cancer, where studies are comparing new combinations against current standards to improve response and survival.

• Trials in lung cancer are evaluating approaches for tumors with specific molecular features such as EGFR, KRAS, and HER2 alterations.
• Studies in metastatic colorectal cancer are testing personalized regimens for mutation-selected disease and treatment-resistant cases.
• Additional research is exploring bladder cancer and ovarian cancer, with the goal of improving disease control and delaying progression.

These trials reflect a strong interest in precision oncology, combining modern immune-based and molecularly targeted approaches to better match treatment to each disease profile.

The research program also includes studies aimed at improving supportive care, preventing disease relapse, and refining how treatment benefit is measured. This includes work in metabolism, physiological processes, and diagnostic techniques, alongside disease-focused trials in cancer and blood disorders.

• Some studies are assessing maintenance strategies and adjuvant approaches intended to reduce recurrence after initial treatment.
• Other trials are using biomarkers and circulating tumor DNA to help guide treatment decisions and monitor response more precisely.
• Research in migraine and immune-mediated disorders broadens the site’s portfolio beyond oncology, while still focusing on better symptom control and treatment effectiveness.

Overall, the site combines advanced therapeutic research with efforts to improve monitoring, personalization, and long-term patient outcomes.